CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 88 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q4 2019. The put-call ratio across all filers is 0.32 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $146,828,000 | +0.3% | 1,240,000 | 0.0% | 0.58% | -8.6% |
Q4 2020 | $146,456,000 | +6.3% | 1,240,000 | 0.0% | 0.63% | -10.1% |
Q3 2020 | $137,814,000 | +8.8% | 1,240,000 | 0.0% | 0.70% | -7.4% |
Q2 2020 | $126,703,000 | +18.6% | 1,240,000 | +25.3% | 0.76% | -4.1% |
Q1 2020 | $106,851,000 | -7.3% | 990,000 | 0.0% | 0.79% | +4.6% |
Q4 2019 | $115,216,000 | +1.7% | 990,000 | 0.0% | 0.75% | -9.3% |
Q3 2019 | $113,325,000 | +20.1% | 990,000 | 0.0% | 0.83% | +23.1% |
Q2 2019 | $94,347,000 | +4.4% | 990,000 | 0.0% | 0.67% | +7.8% |
Q1 2019 | $90,338,000 | +20.2% | 990,000 | 0.0% | 0.62% | +20.9% |
Q4 2018 | $75,151,000 | -5.1% | 990,000 | 0.0% | 0.52% | +12.1% |
Q3 2018 | $79,200,000 | -19.5% | 990,000 | 0.0% | 0.46% | -10.8% |
Q2 2018 | $98,337,000 | +22.6% | 990,000 | 0.0% | 0.52% | +17.5% |
Q1 2018 | $80,190,000 | +2.8% | 990,000 | 0.0% | 0.44% | -8.1% |
Q4 2017 | $77,982,000 | +2184.2% | 990,000 | +2576.0% | 0.48% | +2295.0% |
Q3 2017 | $3,414,000 | – | 36,995 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kite Lake Capital Management (UK) LLP | 207,382 | $24,135,000 | 76.46% |
Maso Capital Partners Ltd | 539,597 | $62,798,000 | 20.20% |
York Capital Management Global Advisors, LLC | 1,102,163 | $128,270,000 | 7.40% |
HHLR ADVISORS, LTD. | 2,751,200 | $320,185,000 | 3.99% |
Dalton Investments, Inc. | 15,551 | $1,810,000 | 1.14% |
Athos Capital Ltd | 8,290 | $965,000 | 0.96% |
Myriad Asset Management Ltd. | 67,019 | $7,799,000 | 0.94% |
Temasek Holdings (Private) Ltd | 990,000 | $115,216,000 | 0.75% |
OXFORD ASSET MANAGEMENT LLP | 211,646 | $24,631,000 | 0.68% |
AGF Investments America Inc. | 12,230 | $1,423,000 | 0.47% |